Overview
Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
Background
Ladiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
Indication
No indication information available.
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/06/11 | Phase 4 | Not yet recruiting | Beijing GoBroad Hospital | ||
2025/01/20 | Phase 1 | Recruiting | Dai, Guanghai | ||
2024/07/15 | Phase 3 | Not yet recruiting | Rui-hua Xu, MD, PhD | ||
2024/04/12 | N/A | AVAILABLE | |||
2024/04/02 | Phase 2 | Recruiting | |||
2024/01/26 | Phase 1 | Recruiting | Shanghai Zhongshan Hospital | ||
2024/01/18 | Phase 2 | Not yet recruiting | |||
2023/12/28 | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | ||
2019/07/25 | Phase 2 | Terminated | |||
2018/02/06 | Phase 1 | Recruiting |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||